Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq
Industry
Pharmaceutical Preparations
Location
2401 4 Th Ave., Suite 1050, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 178 % -47.9%
Debt-to-equity 221 % +197%
Return On Equity -489 % -366%
Return On Assets -153 % -154%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.46M shares
Common Stock, Shares, Outstanding 1.46M shares +12096%
Entity Public Float 1.2M USD -89.1%
Common Stock, Value, Issued 84K USD +37.7%
Weighted Average Number of Shares Outstanding, Basic 276K shares
Weighted Average Number of Shares Outstanding, Diluted 276K shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.4M USD -16%
General and Administrative Expense 10.2M USD -13.1%
Operating Income (Loss) -24.6M USD +14.8%
Net Income (Loss) Attributable to Parent -24.1M USD -38.6%
Earnings Per Share, Basic -87.4 USD/shares
Earnings Per Share, Diluted -87.4 USD/shares -3666%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.71M USD -48.5%
Other Assets, Current 256K USD -62.8%
Assets, Current 10.7M USD -44.1%
Property, Plant and Equipment, Net 543K USD -39.3%
Operating Lease, Right-of-Use Asset 4.39M USD -10.1%
Assets 15.6M USD -37.2%
Employee-related Liabilities, Current 1.86M USD -11.5%
Liabilities, Current 6.21M USD -14.1%
Operating Lease, Liability, Noncurrent 4.63M USD -14.2%
Other Liabilities, Noncurrent 0 USD
Liabilities 10.8M USD -14.1%
Retained Earnings (Accumulated Deficit) -248M USD -10.8%
Stockholders' Equity Attributable to Parent 4.76M USD -61.1%
Liabilities and Equity 15.6M USD -37.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.65M USD -246%
Net Cash Provided by (Used in) Financing Activities -1.87M USD +62.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 1.46M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.65M USD -347%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD -30.1%
Deferred Tax Assets, Valuation Allowance 49.2M USD -7.59%
Deferred Tax Assets, Gross 50.1M USD -7.64%
Operating Lease, Liability 5.4M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 7.34M USD -15.8%
Property, Plant and Equipment, Gross 14.5M USD 0%
Operating Lease, Liability, Current 800K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.94M USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.38M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 344K USD +199%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 106K USD -40.4%
Deferred Tax Assets, Net of Valuation Allowance 922K USD -10.2%
Share-based Payment Arrangement, Expense 1.07M USD -51.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%